Local
Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: The Dispatch

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at The Dispatch



